PRINCETON, NJ – Apr. 30, 2015 – Certara®, the global biosimulation technology-enabled drug development consultancy, today announced that its ClinGenuity company has been named a “Cool Vendor” in Gartner, Inc.’s 2015 Life Sciences report1. ClinGenuity was acquired by Synchrogenix, Certara’s regulatory writing company, in January 2015.
“We are delighted that Gartner has recognized us,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “ClinGenuity’s artificial intelligence (AI)-assisted clinical trial writing tools can serve to shorten the new drug application process, helping to bring new therapies to patients faster.”
Synchrogenix, powered by ClinGenuity, uses an AI/natural language recognition and processing engine to identify individual words, parts of speech, word combinations, phrases and phrasing combinations. The system is intelligent enough to analyze previously written documents in order to construct an automated process for developing new clinical study documents and redacting information based on pre-defined process rules. With extremely high accuracy and efficiency, this configurable technology-enabled solution is unmatched in the industry.
“With the introduction of new clinical trial data disclosure regulations, including European Medicines Agency Policy 70, which went into effect at the start of 2015, we are seeing increased demand for our AI-based ClinGenuity Redaction Management System which efficiently removes all the personal patient and company confidential information from reports with 99 percent accuracy, prior to release,” said Keith Kleeman, Synchrogenix president and ClinGenuity founder. “We are working with a growing number of biopharmaceutical companies that are seeking strategic partners to support their global filings. The ClinGenuity technology strengthens our work with those companies.”
One of the four key findings in Gartner’s report was that process optimization in clinical trial startup and writing can have a demonstrable and significant impact on cycle times and the acceleration of deliverables.
This Gartner research report1 focuses on maximizing revenue, improving research efforts, building deep customer relationships through advanced analytics, and optimizing clinical cycle times by improving study startup and clinical writing.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
1 Gartner “Cool Vendors in Life Sciences, 2015” by Stephen Davies and Michael Shanler, 13 April 2015.
About Synchrogenix, Powered by ClinGenuity, a Certara Company
Synchrogenix, Powered by ClinGenuity, a Certara company, encompasses a group of separate entities operating together to provide regulatory and medical writing services to the pharmaceutical, biotech, and medical device industry worldwide. Synchrogenix Information Strategies Inc.; Synchrogenix Europe, Ltd.; and Synchrogenix Philippines, Inc. (SPI) are all wholly owned subsidiaries with an overall governance structure that creates and enforces a global standard of service, technology, and quality.
Certara is a global biosimulation technology-enabled drug development consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.
Ellen Leinfuss, 609-216-9586
Chief Marketing Officer
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions